Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015

News provided by

Apr 23, 2015, 04:05 ET

DUBLIN, April 23, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2015 first quarter financial results on Thursday, May 7, 2015, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss first quarter 2015 financial results and provide a business and financial update.

Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.

Audio webcast/conference call:
U.S. Dial-In Number: +1 877 415 3179
International Dial-In Number: +1 857 244 7322
Passcode: 74301034

A replay of the conference call will be available through May 14, 2015 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 888 286 8010
Replay International Dial-In Number: +1 617 801 6888
Passcode: 39160618

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.

SOURCE Jazz Pharmaceuticals plc